Effect of psychological stress on aging and its implication on the oral cavity : A mini-review

departmental bulletin pape

Additional file 2: Table S1. of Comparison of photon volumetric modulated arc therapy, intensity-modulated proton therapy, and intensity-modulated carbon ion therapy for delivery of hypo-fractionated thoracic radiotherapy

Normal lung dose distribution. Table S2. Dose distribution for the heart and the esophagus. Table S3. Recalculated 4D (doses accumulated from 4D CT phases within the gating window) vs. 3D dose comparison for selected dose parameters for intensity modulated a) carbon ion therapy, and b) proton therapy with the Wilcoxon rank test. (DOC 114 kb

Definitive Upfront Stereotactic Ablative Radiotherapy Combined with Image-Guided, Intensity Modulated Radiotherapy (IG-IMRT) or IG-IMRT Alone for Locally Advanced Non-Small Cell Lung Cancer - Fig 2

<p>The a) overall survival (OS), and b) progression-free survival (PFS) for all patients. The c) local, d) regional, and e) distant control for patients who were treated with SABR ± IG-IMRT. f) Local control following SABR + IG-IMRT vs. that in patients with T_x, T1/2 or T3/4 disease who received IG-IMRT.</p

Illustration of a composite treatment plan for a patient with oligo-metastatic poorly differentiated squamous cell carcinoma (cT1a, N3, M1b).

<p>She received upfront carboplatin/gemcitabine with excellent extra-thoracic response. Subsequently, SABR to her primary disease + IG-IMRT to her regional disease as the only remaining disease following chemotherapy were administered. She remains disease free 2 years after the completion of all treatments.</p

Appalachian Mountaintop Mining Particulate Matter Induces Neoplastic Transformation of Human Bronchial Epithelial Cells and Promotes Tumor Formation

Epidemiological studies suggest that living near mountaintop coal mining (MTM) activities is one of the contributing factors for high lung cancer incidence. The purpose of this study was to investigate the long-term carcinogenic potential of MTM particulate matter (PM_MTM) exposure on human bronchial epithelial cells. Our results show that chronic exposure (3 months) to noncytotoxic, physiological relevant concentration (1 μg/mL) of PM_MTM, but not control particle PM_CON, induced neoplastic transformation, accelerated cell proliferation, and enhanced cell migration of the exposed lung cells. Xenograft transplantation of the PM_MTM-exposed cells in mice caused no apparent tumor formation, but promoted tumor growth of human lung carcinoma H460 cells, suggesting the tumor-promoting effect of PM_MTM. Chronic exposure to the main inorganic chemical constituent of PM_MTM, molybdenum but not silica, similarly induced cell transformation and tumor promotion, suggesting the contribution of molybdenum, at least in part, in the PM_MTM effects. These results provide new evidence for the carcinogenic potential of PM_MTM and support further risk assessment and implementation of exposure control for PM_MTM

Kaplan-Meier estimate of overall survival from time of referral to phase 1 clinic in patients with <i>mutBRAF</i> treated with RAF/MEK targeting agents or other phase 1 trials.

<p>Tic marks represent patients still alive at the last follow-up. (Of 80 patients with <i>BRAF</i> mutations, 56 received a RAF/MEK targeting agents, 11 received a non RAF/MEK targeting agents and 13 were not enrolled on a phase 1 trial).</p

Univariate analysis of survival predictors after referral to phase 1 clinic in patients with <i>mutBRAF</i> advanced cancer.

1<p>Royal Marsden Hospital (RMH) ¹³ prognostic score is determined as follows: 0 points, normal lactate dehydrogenase (LDH), albumin ≥3.5 g/dL, a ≤2 metastatic sites; 1 point- LDH>upper limit of normal, albumin <3.5 g/dL, >2 metastatic sites. Patients with 0–1 points had a good RMH score, and patients with 2–3 points had a poor RMH score.</p>2<p>Includes patients treated with other agents (N = 11) as well as patients who never started on phase 1 trial (N = 13).</p>3<p>One patient of whom the exact date of diagnosis was not documented was excluded only from the univariate analysis comparing the OSref between patients who had a time from diagnosis to metastasis less or more than 2 years.</p>4<p>Patients who never had a restaging at the last follow-up or who never started on a phase 1 trial were excluded in the univariate analysis (N = 22).</p

Forest plot summarizing the clinical factors affecting overall survival after referral and displaying their hazard ratio and 95% Confidence interval calculated by Cox proportional hazards regression model in patients with <i>wtBRAF</i> advanced cancer.

<p>Forest plot summarizing the clinical factors affecting overall survival after referral and displaying their hazard ratio and 95% Confidence interval calculated by Cox proportional hazards regression model in patients with <i>wtBRAF</i> advanced cancer.</p

Multivariate analysis by logistic regression model showing the clinico-pathological features correlated with the <i>BRAF</i> mutation.

<p>Multivariate analysis by logistic regression model showing the clinico-pathological features correlated with the <i>BRAF</i> mutation.</p

Clinical characteristic of 80 patients with <i>BRAF</i>-mutant disease and 149 matched controls with <i>BRAF</i>-wild-type (Univariate Analysis).

1<p>Denominator refers to the number of patients tested.</p